Nephrology MCQs-11

---

Nephrogenic systemic fibrosis is likelyto occur in patients with renal impairment who has undergone

---

A. CT Scan

B. MRI Scan

C. Contrast-enhanced ultrasonography

D. PET Scan

---

---

Which of the following Gadolinium-based contrast agents is categorized as very low risk for associated risk of Nephrogenic systemic fibrosis

---

A. Gadodiamide

B. Gadopentetate dimeglumine

C. Gadoversetamide

D. Gadobutrol

---

---

All are TRUE about Nephrogenic systemic fibrosis EXCEPT

---

A. Typically involves the dermis in the extremities symmetrically

B. Commonest site of involvement is face

C. Skin lesions are hyperpigmented

D. Skin is primarily involved

---

---

ALL are TRUE for Macrocyclic Gadolinium contrast agents in MRI EXCEPT

---

A. Less chemical instability than linear agents

B. Lower risk of nephrogenic systemic fibrosis

C. Lower gadolinium deposition

D. Lower risk of allergic reactions

---

---

The ACR has divided gadolinium-based contrast agents into three groups depending on the risk of nephrogenic systemic fibrosis

---

Group I (greatest number of reported nephrogenic systemic fibrosis cases)

---

1. gadodiamide (Omniscan)
2. gadopentetate dimeglumine (Magnevist)
3. gadoversetamide (OptiMARK)

---

Group II (few, if any, cases of nephrogenic systemic fibrosis)

---

1. gadobenate dimeglumine (MultiHance)
2. gadobutrol (Gadovist, Gadavist)
3. gadoterate meglumine (Dotarem, Clariscan)
4. gadoteridol (ProHance)

---

Group III (few, if any cases of nephrogenic systemic fibrosis but limited data available)

---

• gadoxetate disodium (Eovist, Primovist )

---